GlassScriptPhysician profile
Kirt Munson
NPI 1396230124
$107,632.04
in general payments reported to CMS, 2019-2025
42 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28K · 2022: $25K · 2023: $16K · 2024: $18K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $12K · Travel and Lodging: $902 · Consulting Fee: $675 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,275.00 |
| Food and Beverage | $12,432.00 |
| Travel and Lodging | $902.10 |
| Consulting Fee | $675.00 |
| Education | $270.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $67,839.72 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $14,652.47 | 2021 | |
| Pfizer INC. | $10,407.02 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,659.92 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $1,408.98 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $1,346.79 | 2021-2022 | |
| Ucb, INC. | $1,164.24 | 2021-2025 | Briviact, Nayzilam |
| Sk Life Science, INC. | $918.47 | 2021-2025 | Xcopri |
| Lilly USA, LLC | $769.89 | 2021-2025 | Emgality, Reyvow, Amyvid |
| Lundbeck LLC | $522.09 | 2021-2025 | Vyepti |
| Harmony Biosciences LLC | $421.05 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $381.67 | 2021-2025 | Rytary, Brekiya |
| Axsome Therapeutics, INC. | $366.98 | 2023-2025 | Symbravo, Sunosi, Auvelity |
| Biogen, INC. | $346.09 | 2021-2025 | Vumerity, Tysabri |
| Eisai INC. | $331.94 | 2023-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirt Munson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.